284 related articles for article (PubMed ID: 25445636)
1. Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
Appelbaum FR; Anasetti C; Antin JH; Atkins H; Davies S; Devine S; Giralt S; Heslop H; Laport G; Lee SJ; Logan B; Pasquini M; Pulsipher M; Stadtmauer E; Wingard JR; Horowitz MM
Biol Blood Marrow Transplant; 2015 Feb; 21(2):202-24. PubMed ID: 25445636
[No Abstract] [Full Text] [Related]
2. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
Fuerst D; Mueller C; Beelen DW; Neuchel C; Tsamadou C; Schrezenmeier H; Mytilineos J
Haematologica; 2016 Feb; 101(2):241-7. PubMed ID: 26611475
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilia indicates the evolution to acute graft-versus-host disease.
Basara N; Kiehl MG; Fauser AA
Blood; 2002 Oct; 100(8):3055. PubMed ID: 12382649
[No Abstract] [Full Text] [Related]
5. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
6. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Kussman A; Shyr D; Hale G; Oshrine B; Petrovic A
Pediatr Blood Cancer; 2019 Jan; 66(1):e27481. PubMed ID: 30318867
[TBL] [Abstract][Full Text] [Related]
8. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
Thakral B; Muzzafar T
Blood; 2017 Jul; 130(2):231. PubMed ID: 28705862
[No Abstract] [Full Text] [Related]
10. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Rashidi A; Ali AM; Vij KR; Shanley R; Romee R; Cooley SA; Westervelt P; DiPersio JF; Miller JS; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Sep; 92(9):E549-E552. PubMed ID: 28568483
[No Abstract] [Full Text] [Related]
12. Variation in inpatient costs of hematopoietic cell transplantation among transplant centers in the United States.
Thao V; Kozhimannil KB; Thomas W; Golberstein E
JAMA Intern Med; 2014 Aug; 174(8):1409-12. PubMed ID: 24934623
[No Abstract] [Full Text] [Related]
13. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
14. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M; de Wreede LC; Halkes CJ; von dem Borne PA; Kersting S; Marijt EW; Veelken H; Putter H; Schetelig J; Falkenburg JH
Haematologica; 2016 Apr; 101(4):506-14. PubMed ID: 26802054
[TBL] [Abstract][Full Text] [Related]
15. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
16. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
D'Angelo CR; Hall A; Woo KM; Kim K; Longo W; Hematti P; Callander N; Kenkre VP; Mattison R; Juckett M
Leuk Res; 2020 Sep; 96():106419. PubMed ID: 32683127
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
Phillips GL
Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
Couban S; Simpson DR; Barnett MJ; Bredeson C; Hubesch L; Howson-Jan K; Shore TB; Walker IR; Browett P; Messner HA; Panzarella T; Lipton JH;
Blood; 2002 Sep; 100(5):1525-31. PubMed ID: 12176866
[TBL] [Abstract][Full Text] [Related]
20. Transplant for MDS: challenges and emerging strategies.
Tamari R; Castro-Malaspina H
Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
